Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review

• Published in: International journal of oral science Vol. 12; no. 1; p. 2
• Main Authors: Cheng, Ran, Wu, Zhiwu, Li, Mingming, Shao, Meiying, Hu, Tao
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 02.01.2020; Springer Nature B.V
• Subjects: 631/154/555; 631/80/304; 692/699/3020/3029; Bone resorption; Cryopyrin; Cytokines; Dentistry; Diabetes mellitus; Diabetes Mellitus, Type 2; Gout; Gum disease; Humans; IL-1β; Inflammation; Inflammation - immunology; Inflammation - therapy; Interleukin-1beta - antagonists & inhibitors; Interleukin-1beta - drug effects; Interleukin-1beta - immunology; Medicine; Oral and Maxillofacial Surgery; Orthopedics; Periodontitis; Periodontitis - diagnosis; Periodontitis - therapy; Review; Review Article; Rheumatoid arthritis; Surgical Orthopedics; Therapeutic applications
• ISSN: 1674-2818; 2049-3169; 2049-3169
• DOI: 10.1038/s41368-019-0068-8

Interleukin(IL)-1β, a pro-inflammatory cytokine, was elevated and participates in periodontitis. Not only the link between IL-1β and periodontitis was proved by clinical evidence, but also the increased IL-1β triggers a series of inflammatory reactions and promotes bone resorption. Currently, IL-1β blockage has been therapeutic strategies for autoimmune and autoinflammatory diseases such as rheumatoid arthritis, cryopyrin-associated periodic syndromes, gout and type II diabetes mellitus. It is speculated that IL-1β be a potential therapeutic target for periodontitis. The review focuses on the production, mechanism, present treatments and future potential strategies for IL-1β in periodontitis.